Biodel Abstracts to be Presented at 46th Annual Meeting of European Association for the Study of Diabetes
DANBURY, Conn., July 1 /PRNewswire-FirstCall/ -- Biodel Inc.
(NASDAQ: BIOD) announced today that the
following abstracts describing results from studies of the
company's product candidates have been accepted for presentation in
September during the 46th annual meeting of the European
Association for the Study of Diabetes in Stockholm.
Oral Presentation:
#OP 01, Oral session on novel formulations and delivery of
insulin, Tuesday, September 21, 2010 10:45 AM - 12:15 PM "A novel
pH-neutral formulation of the monomeric insulin VIAject® has a
faster onset of action than insulin lispro"; to be presented by Dr.
T. Heise, Profil Institut fur Stoffwechselforschung GmbH, Neuss,
Germany
Poster Presentations:
#PS 089 Poster session on short-acting insulins, Thursday,
September 23, 2010 12:30 PM - 1:30 PM "Biocompatibility of the
ultra-rapid insulin VIAject® with continuous insulin infusion
sets"; to be presented by Dr. F. Flacke, Biodel, Inc.
#PS 089 Poster session on short-acting insulins, Thursday,
September 23, 2010 12:30 PM - 1:30 PM "Pharmacokinetics of novel
formulations of insulin analogs that provide a more rapid onset of
action in diabetic miniature swine"; to be presented by Dr. R.
Pohl, Biodel, Inc.
The abstracts can be accessed through the association's website,
www.easd.org.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on
the development and commercialization of innovative treatments for
diabetes. Biodel's product candidates are developed using
VIAdel(TM) technology, which reformulates existing FDA-approved
peptide drugs. Biodel's new drug application for its most advanced
product candidate, VIAject®, has been accepted for review by
the FDA with a Prescription Drug User Fee Act action date of
October 30, 2010. Earlier-stage product candidates include
VIAtab(TM), a sublingual tablet formulation of insulin, a line of
basal insulins, and a stabilized formulation of glucagon. For
further information regarding Biodel, please visit the company's
website at www.biodel.com.
BIOD-G Contact: Seth Lewis Vice President The Trout Group, LLC (646) 378-2852
Source: Biodel Inc.
CONTACT: Seth Lewis, Vice President, The Trout Group, LLC,
+1-646-378-2852
Web Site: http://www.biodel.com/
Posted: July 2010
